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Abstract
Background: Systemic sclerosis (SSc) is a rare connective tissue disease associated with rapid evolving interstitial
lung disease (SSc-ILD), driving its mortality. Specific biomarkers associated with the evolution of the lung disease
are highly needed. We aimed to identify specific biomarkers of SSc-ILD to predict the evolution of the disease.
Nucleosomes are stable DNA/protein complexes that are shed into the blood stream making them ideal candidates
for biomarkers.
Methods: We studied circulating cell-free nucleosomes (cf-nucleosomes) in SSc patients, 31 with ILD (SSc-ILD) and
67 without ILD. We analyzed plasma levels for cf-nucleosomes and investigated whether global circulating
nucleosome levels in association with or without other biomarkers of interest for systemic sclerosis or lung fibrosis
(e.g., serum growth factors: IGFBP-1 and the MMP enzyme: MMP-9), could be suitable potential biomarkers for the
correct identification of SSc-ILD disease.
Results: We found that H3.1 nucleosome levels were significantly higher in patients with SSc-ILD compared SSc
patients without ILD (p < 0.05) and levels of MMP-9 were significantly increased in patients with SSc-ILD compared
to SSc patients without ILD (p < 0.05). Conversely, IGFBP-1 was significantly reduced in patients with SSc-ILD
compared to SSc without ILD (p < 0.001). The combination of cf-nucleosomes H3.1 coupled to MMP-9 and IGFBP-1
increased the sensitivity for the differential detection of SSc-ILD. High levels of accuracy were reached with this
combined model: its performances are strong with 68.4% of positive predictive value and 77.2% of negative
predictive value for 90% of specificity. With our model, we identified a significant negative correlation with FVC %
pred (r = −0.22) and TLC % pred (r = −0.31). The value of our model at T1 (baseline) has a predictive power over
the Rodnan score at T2 (after 6-18 months), showed by a significant linear regression with R2 = 19% (p = 0.013). We
identified in the sole group of SSc-ILD patients a significant linear regression with a R2 = 54.4% with the variation of
DLCO between T1 and T2 (p < 0.05).
Conclusion: In our study, we identified a new blood-based model with nucleosomic biomarker in order to
diagnose SSc-ILD in a SSc cohort. This model is correlated with TLC and FVC at baseline and predictive of the skin
evolution and the DLCO. Further longitudinal exploration studies should be performed in order to evaluate the
potential of such diagnostic and predictive model.
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Introduction
Systemic sclerosis (Ssc) is a rare inflammatory disease of
unknown origin associated with multi-organic involve-
ment [1]. The main complication of SSc driving the
morbi-mortality of the disease is the particular appear-
ance of interstitial lung disease (ILD) [2]. The clinical
history of SSc associated interstitial lung disease (SSc-
ILD) can vary from a slow evolving lung disease to a
quick flare up and deterioration. Treatment is based on
aggressive immunosuppression only proposed in cases of
progressive lung disease. Nowadays, in the more severe
cases, an autologous hematopoietic stem cell transplant-
ation can be recommended [3]. The problem, as in other
interstitial lung diseases [4, 5], is to identify patients at
increased risk of progression for early therapeutic
intervention.
SSc is typically associated with vascular inflammation
and fibrosis [6]. Its clinical classification is based on skin
fibrosis extension separating patients in two different
patterns: Limited cutaneous systemic sclerosis (lcSSc)
characterized by a skin fibrosis restricted to distal areas
to the elbows and knees. The second one is the diffuse
cutaneous systemic sclerosis, which is associated with
the involvement of proximal areas, the face, and the
trunk in addition to distal areas.
Biological markers, often referred as biomarkers, are
commonly defined as objectively measured elevated indi-
cators of physiological/pathological processes or pharma-
cological response to therapeutic intervention [4].
Biomarkers remain urgently needed as tools for differ-
ential diagnosis, prognosis, and disease progression and
as therapeutic response predictors. Although anti-
nuclear antibodies (ANA) were the first biomarkers
available in Sscl, they still are unhelpful for the assess-
ment of disease activity and treatment response.
Nucleosomes are the basic unit of chromatin consisting
in a 147 bp DNA strand wrapped around a protein octa-
mer of core histones (H2A, H2B, H3, and H4). Nucleo-
somes are released from dying or stressed cells into blood
circulation. Elevated nucleosome levels are often found in
various cancer and in acute and chronic non-malignant
inflammatory diseases [7, 8]. Even if elevated levels of cir-
culating cell-free nucleosomes (cf-nucleosomes) does not
appear to be specific to a unique pathological state and
correlate with different mechanisms of release, it may be
of a particular interest for differential diagnosis and may
serve as a guiding biomarker for prognosis in association
with other biomarkers as it is sensitive and linked with in-
flammatory processes [9–12]. Reinforcing this hypothesis,
Yoshizaki et al. identified a significant increase in cell-free
nucleosomic biomarkers in SSc with a specific correlation
with the skin involvement [13].
In this study, we investigated whether there was an asso-
ciation between the level of circulating H3.1 containing
nucleosomes and other biomarkers of interest in sys-
temic sclerosis or lung fibrosis such as the serum
growth factors IGFBP-1 and the MMP enzyme MMP9,




We selected 98 samples from patients with SSc initially
recruited for a previous study (2010 to 2018) focusing
on biomarkers in SSc from our ambulatory care policli-
nic at CHU Liege. The patients were divided into 2
groups: SSc patients without any lung involvement (SSc,
n = 67) and patients suffering from SSc associated with
interstitial lung disease (SSc-ILD, n = 31). The diagnosis
of SSc was made according to the international recom-
mendations of ACR/Eular [20, 21]. Patients were divided
in two groups according to their HRCT scan to deter-
mine the presence of ILD. Lung involvement was evalu-
ated using the respiratory function test, HRCT scan,
bronchoalveolar lavage (when available), and the clinical
history of the patient. We excluded all other causes of
interstitial lung disease (such as asbestosis, idiopathic
pulmonary fibrosis, hypersensitivity pneumonitis, or
toxic pneumonitis). Then, we compared the baseline
level of biomarkers (T1) with the time 2 (T2) level of
biomarkers collected between 6 and 18 months after T1
(median: 11 months and 22 days).
The protocol was approved by the ethics committee of
CHU of Liège, and all subjects gave written consent for
their enrollment (Belgian number: B707201422832; ref:
2014/302).
Pulmonary function tests
We performed lung function tests in our routine respira-
tory laboratory of CHU Liège. All spirometric tests
performed for this study were measured using the
pneumotachograph Jaeger Master lab system (Erich Jaeger
GmbH, Wuzburg, Germany). The forced expiratory vol-
ume in one second (FEV1) and forced vital capacity (FVC)
were measured in accordance with the recommendations
of the European Respiratory Society (ERS) [22]. The re-
sults were expressed in milliliter and percent predicted.
The Tiffeneau index or FEV1/FVC was expressed in per-
cent. The total lung capacity (TLC) was measured by body
plethysmography according to ERS recommendations
(Erich Jaeger GmbH, Wuzburg, Germany). The diffusion
capacity of CO (DLCO) and the report DLCO/AV (alveo-
lar volume) were measured by the single-breath carbon
monoxide gas transfer method and expressed as percent
predicted (SensorMedics2400He/CO Analyzer System,
Bilthoven, Netherlands).
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Biomarkers measurements in serum
Level of IGFBP-1 was assessed by ELISA multiplex using
Fluorokine-1 as referred to our previous study [18]. The
detection limit for this assay was 170 pg/ml. Likewise,
the concentration of MMP-9 was analyzed with DuoSet
kit (R&D systems). The lower detection limit for this kit
was 25 pg/ml. Levels of blood biomarkers were evaluated
at baseline (T1) and after 6-18 months (T2).
Biomarker measurements in plasma
Cell-free nucleosome levels were measured using Nu.Q™
H3.1 ELISA kit (Belgian Volition SPRL, Isnes, Belgium)
according to the manufacturer’s instructions. In brief,
plasma samples (20 μl in duplicate) were incubated for 2
h 30 min at room temperature in a 96-well microtiter
plate coated with a monoclonal antibody raised again a
Histone H3.1 epitope. After washing steps, the level of
cf-nucleosomes was quantified by adding a biotinylated
anti-nucleosome detection antibody directed to a nucleo-
some conformational epitope (incubation 90min at room
temperature). The wells were washed and streptavidin-
horseradish peroxidase (HRP) was added. After incubation
for 30min at room temperature, the wells were washed
and a peroxidase substrate-2,2′-azino-bis-(3-ethylben-
zothiazolonine-6 sulfonic acid) was added. The optical
densities of the wells were read with a Spectramax ID5
microplate reader (Molecular Devices).
Statistical analysis
All statistics were computed with the software IBM SPSS
Statistics, version 26.0.0.0. The majority of the tests per-
formed were nonparametric, using binomial distribution
and natural logarithms (logistic regression), mean ranks,
medians, and/or interquartile ranges. Cumulative perfor-
mances of plasma cf-nucleosomes and serum biomarkers
were evaluated using multivariate predictive analysis. For
this, models were developed with Binary Logistic Regres-
sion (stepwise/backward method; Wald and chi-square
statistics), providing the most discriminant single bio-
markers or combinations of biomarkers, and giving back
probabilities of suffering from SSc-ILD in relation to SSc
for each patient and each model computed. XY plots
Table 1 Subjects characteristics
SSc (n = 67) SSc-ILD (n = 31)
Age, years 56 ± 12 60 ± 13
Gender (M/F) 17/50 6/25
BMI, kg/m2 25 ± 4 25 ± 4
Smokers (NS/FS/S) (%) 48/28/24 55/28/17
Paq-year 15 ± 17 6.9 ± 8.4
CRP 1.7 (0.7-5.1) 2.4 (1.1-6.1)
FEV1 post-BD, % pred 98 ± 22 88 ± 23*
FVC post-BD, % pred 104 ± 20 90 ± 22**
FEV1/FVC post-BD, % pred 78 ± 10 81 ± 8
TLC, % pred 101 ± 15 85 ± 19***
TLCo % pred 71 ± 20 56 ± 16**
KCO % pred 79 ± 19 74 ± 14
HRT extent (% lung) / 5 (5-25)
IT, immunosupressive therapy (%) 14 38
OCS, oral cortico steroide (%) 24 28
Prednisolone equivalent (mg) 5 (5-5) 10 (5-10)
GI tract score, none/mild/severe (%)1 36/62/2 16/80/4
Disease duration (year) 6.93 ± 8.47 5.55 ± 5.87




Musculoskeletal involvement (%) 22 21
Renal crisis (%) 6.8 0
Cardiac involvement (%) 2 37
Data are expressed as mean ± SD
NS non-smoker, FS former smoker, S smoker, IT immunosuppressive therapy
(mycophenolate mofetil, methotrexate, cyclophosphamide), SSc systemic
sclerosis, lcSSc limited cutaneous, dSSc diffuse cutaneous SSc, SS
sine scleroderma
°Values are expressed as mean ± SD when parametrics and median (IQR)
when non parametrics
1GI tract score, missing value: SSc 20/67; SSc-ILD 12/31
*p < 0.05
**p < 0.01
***p < 0.001 compared to healthy subjects
Table 2 Levels blood biomarkers
Biomarkers T1 (n = 98) T2 (n = 37)
SSc (n = 67) SSc-ILD (n = 31) Sig. SSc (n = 27) SSc-ILD (n = 10) Sig.
Median IQR Median IQR Median IQR Median IQR
MMP-9 820.5 435-1354 1243.4 887-1724 * 1164.9 389-1599 903.14 366-1647
IGFBP-1 14.96 8.6-25.5 5.74 2.2-14.3 *** 11.04 7.3-24.6 5.6 2.7-33.1
H3.1 66.4 41-102 82.6 65-146 * 56.2 41-79 77.6 55-172 *
The levels of IGFBP-1, MMP-9, and H3.1 containing cf-nucleosomes (median and IQR) were evaluated at T1 and T2 for SSc and SSC-ILD patients. Significant
differences were observed between SSc and SSc-ILD patients for all three biomarkers at T1. At T2, only the level of H3.1 containing cf-nucleosome remained
significantly higher in SSc-ILD patients
P values were determined by Mann-Whitney rank-sum test
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were done to express the results in terms of real data,
with an estimation of each biomarker/model’s predictive
power on respiratory function levels using simple linear
regression and FIT curves (prediction lines).
Results
Subject demographic and functional characteristics
The demographic, functional, and treatment characteris-
tics of the subjects are given in Table 1. Whereas the
mean age of patient is similar between SSc and SSc-ILD,
SSC-ILD exhibit a lower TLC and FVC than those with-
out ILD (p < 0.001 and p < 0.01 respectively) with a re-
duced DLCO compared to those with preserved lung
parenchyma (p < 0.01).
Circulating cell-free nucleosome levels in SSc and SSc-ILD
We found that the baseline H3.1 nucleosome levels were
significantly higher in patients with SSc-ILD compared
to patients with SSc without ILD (Table 2; Fig. 1a; p <
0.05). The area under the ROC curve (AUC) for cf-
nucleosomes H3.1 was 0.68 for the discrimination of
SSc-ILD vs. SSc group (Supplementary Figure 1).
Protein biomarkers
We identified that serum levels of MMP-9 were signifi-
cantly increased in SSc-ILD compared to SSc patients (p
< 0.05) (Table 2; Fig. 1b). Conversely, IGFBP-1 was sig-
nificantly reduced in SSc-ILD compared to SSc (p <
0.001) (Table 2; Fig. 1c).
Cumulative performance of cf-nucleosomes and serum
biomarkers
The best model was found by combining H3.1 contain-
ing cf-nucleosome and MMP-9 and IGFBP-1 levels. It
increased the sensitivity for the differential detection of
the SSc-ILD to 42% at 90% specificity with an area under
the curve of 0.77 compared with the best single assay
sensitivity at 32% observed with the H3.1 containing cf-
nucleosome (Fig. 2a and Table S2). Box plot showed a
significant higher score in patients with SSc-ILD than
SSc patients without ILD (Fig. 2b, p < 0.001).
High levels of accuracy were reached with this com-
bined model: with 68.4% positive predictive value and
77.2% negative predictive value for at 90% specificity.
We also tested a model including the gender as a sup-
plementary explanatory variable in the model combining
the three biomarkers to explain SSc-ILD in relation to
SSc (Supplementary Figure 2). Gender is not significant
(p = 0.269) in this new model, and the prediction power
is not statistically improved (R2 = 29.4%) (data not
shown). However, the gender seems having an impact
on the levels of the combined model with Nu.Q H3.1,
IGFBP-1, and MMP-9 only in the SSc-ILD group: a two-
way ANOVA showed an interaction between the gender
and the disease (p = 0.027) on the probability of SSc-
ILD provided by the model (Supplementary Figure 2).
The probability of SSc-ILD is higher for males than for
females in the SSc-ILD group. Nevertheless, the inter-
pretations of these results should be cautious because of
the great difference of sizes between groups (SSc group:
Fig. 1 Individual biomarkers in the blood of SSc compared to SSc-
ILD at baseline. Boxplot expressing medians and IQ range for each
biomarker in function of diagnosis at T1. The box plots showed
significantly higher levels for H3.1 containing cf-nucleosomes (a) and
MMP-9 (b) in patients with SSc-ILD (n = 31) compared with SSc
patients (n = 67) (p < 0.05 for both), in contrast IGFBP-1 (c) was
significantly lower level in patient with SSc-ILD (p < 0.001). P values
were determined by Mann-Whitney rank-sum test. The box plot
shows the median and the 25th and 75th percentiles; the whiskers
indicate 1.5 times the interquartile range (IQR)
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50 females and 17 males; SSc-ILD group: 25 females and
6 males).
In addition, models with only two out of the three bio-
markers were also evaluated (Supplementary Figure 3).
Nevertheless, by comparing the area under the curve,
the sensitivity at 90% specificity, and the coefficient of
determination R2 of these models, none of them was
better than the model combining H3.1 containing cf-
nucleosome and MMP-9 and IGFBP-1 levels.
Correlation between biomarkers and pulmonary function
tests
Correlations between H3.1 containing cf-nucleosomes,
IGFBP-1, and MMP-9 in the global cohort compared to
PFTs are represented in the supplementary material
(Table S1). At baseline level, IGFBP-1 was positively cor-
related with TLC (% pred) (r = 0.267) and negatively
correlated with KCO (DLCO/VA) (r = −0.247). We did
not find any correlation for MMP-9.
For cf-nucleosome, we identified a negative correlation
with DLCO (r = −0.272) and a positive correlation with
Rodnan skin score (r = 0.268) [23]. At T2, H3.1 containing
cf-nucleosome levels was negatively correlated with TLC
(% pred) (r = −0.413) and positively correlated with Rodnan
score (r = 0.454). Of note, we did not find any correlation
between the two other biomarkers and PFT at T2.
Predictive value of the model
We identified with our combination of three biomarkers a
significant correlation with FVC (% pred) and TLC (% pred)
(Fig. 3). Our model was negatively correlated with FVC (r =
−0.218) and with TLC (r = −0.315). At T2, the model is
even more negatively correlated with TLC (% pred) (r =
−0.431) but not with other parameters (Table 3). When
split by groups (SSc or SSc-ILD), the highest significant cor-
relations are found for SSc-ILD patients: the model is nega-
tively correlated with TCL (% pred) (r = −0.576).
Moreover, the value of our model at T1 has a predictive
power over the Rodnan score at T2, showed by a signifi-
cant linear regression with R2 = 19% (p = 0.013) (Fig. 4a).
Then, we evaluated the predictive power of our model
over the PFT evolution between T1 and T2 as a potential
reliable predictor of the disease prognostic. We identified
in the sole group of SSc-ILD patients a significant linear
regression with a R2 = 54.4% with the variation of DLCO
between T1 and T2 (p < 0.05) (Fig. 4b).
Discussion
In our study, we identified a new blood-based model
combining H3.1 containing cf-nucleosomes, IGBP-1 and
MMP-9 as biomarkers to diagnose SSc-ILD in a SSc co-
hort. This model is correlated with TLC and FVC at
baseline and is a consistent predictor of the skin evolu-
tion and the DLCO in SSc-ILD patients.
We identified an increased level of circulating H3.1
containing cf-nucleosome in SSc-ILD patients compared
to SSc. Of interest, cf-nucleosome H3.1 was negatively
correlated with DLCO (% pred) and positively correlated
with Rodnan score. Focusing on DLCO analysis, this has
been made on a small cohort, which limited the impact
of the analysis. Of interest, this observation is in line
with a previous study of Yoshizaki et al. who identified a
Fig. 2 Roc curve and box plot for discrimination of SSc vs SSc-ILD in the combination of H3.1 containing cf-nucleosome associated with IGFBP-1
and MMP-9. A model with three biomarkers: H3.1 containing cf-nucleosome, MMP-9, and IGFBP-1 discriminated patients with scleroderma with
fibrosis (SSc-ILD) versus scleroderma without fibrosis (SSc): a ROC curves for discrimination of SSc-ILD patients vs SSc patients. The model reached
a sensitivity of 58% and 42% at respectively 80% specificity and 90% specificity. The AUC was 0.77 (pModel < 0.001; pNu.Q H3.1 = 0.022; pMMP-9 =
0.047; pIGFBP-1 = 0.01). b Box plot demonstrating significantly higher score in patients with a SSC-ILD (n = 31) compared with SSc patients (n = 67)
(p < 0.001). The score for each group was achieved with pre-processed ELISA data from Nu.Q™ H3.1, MMP-9, and IGFBP-1 assays. A binary logistic
regression model was used to calculate the probability of SSc-ILD in relation to SSc. P values were determined by Mann-Whitney rank-sum test.
The box plot shows the median and the 25th and 75th percentiles; the whiskers indicate 1.5 times the interquartile range (IQR)
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Fig. 3 Correlation of the combined model IGFBP-1, MMP-9, and H3.1 containing cf-nucleosomes against FVC (% pred) and TLC (% pred).
Significant negative correlations are observed with FVC (r = −0.218, p < 0.01) and with TLC (r = −0.315, p < 0.05)
Table 3 Correlations between the model and PFT at baseline
The level of the combined model with IGFBP-1, MMP-9, and H3.1 containing cf-nucleosomes (probability of SSC-ILD) computed at T1 was evaluated in relation to
PFT for all patients. Significant negative correlations are observed between the model and FVC (% pred) and TLC (% pred). The negative correlation is still
significant and even stronger between the model computed with T1 measurements and TLC (% pred) quantified at T2 (but not with FVC at T2), which means that
the model could be a predictor of disease progression for TLC (% pred) at T2
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significant increase in cell-free nucleosomic biomarkers
in SSc with a specific correlation with the skin involve-
ment [13]. In our study, instead of using total cell-free
circulating nucleosomes, we used a specific H3 variant
assay (Nu.Q™ H3.1) which seems to increase sensibility
compared to our previous study [5]. Contrarily to our
previous findings focusing on IPF, we identified an in-
crease in cf-nucleosome levels, which is in keeping with
the physiopathology of SSc. Indeed, the lung fibrosing
process is associated with lung inflammation recognized
in SSc per se. Knowing that we are not surprised that
the global level of cf-nucleosome was increased as it is
generally described in systemic inflammatory diseases
due to the immune activation [8, 24–26]. This observa-
tion is in line with the treatment benefit with
immunosuppressive therapies shown in SSc-ILD con-
versely to what is seen in IPF [22].
Nucleosomes may play direct and indirect roles in im-
munological abnormalities associated with SSc, which
could be independent of the antigen-specific pathway [8,
25, 27]. By associating these biomarkers with inflamma-
tory and fibrosis biomarkers, we could expect an increase
accuracy to diagnose SSc patients. Indeed, SSc is a highly
complex disease with an involvement of multiple path-
ways like inflammatory and fibrosis process [28].
In our study, we showed that MMP-9 was increased
in SSC-ILD compared to SSC patients. Matrix
metalloproteinase-9 (MMP-9) has been implicated in
the pathogenesis of cancer, autoimmune disease, and
various pathologic conditions characterized by excessive
Fig. 4 Predictive value of the model. Linear regression with the model as an explanatory variable for PFT. a A significant linear regression with all
patients (SSc + SSc-ILD), p = 0.013, with R2 = 19%; the score of the model H3.1 containing cf-nucleosome, IGFBP-1, MMP-9 at T1 has a predictive
power over the Rodnan score at T2 (n = 32, nSSc = 24, and nSSc-ILD = 8). b A Significant linear regression with p = 0.023 and R
2 = 54.4% was
observed for the SSc-ILD group: variations of DLCO between T1 and T2 is explained by the variation of the model between these two-time
points (n = 9)
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fibrosis. Kim et al. suggested that the enhanced produc-
tion of MMP-9 may contribute to fibrogenic remodeling
during the progression of fibrosis in SSc [29] by its action
of metalloproteinase. Confirmatory to our findings, MMP-
9 is also known to be elevated in BALF of SSc-ILD pa-
tients compared to those without ILD [30]. Therefore,
MMP-9 could be a specific marker of SSc-ILD activity
and would benefit to be specifically studied in one other
study.
IGFBP-1 has not been much studied in SSc-ILD so far.
Nevertheless, IGF-I is known to be associated with the
fibroblastic activity in SSc [31, 32]. The IGFBPs carry
IGFs and can increase their half-life, alter their function
(in potentiating or inhibiting it), or facilitate their pas-
sage to the target tissues [33]. Focusing on those results,
we hypothesize that those lower levels of blood IGFBP-1
seen in SSc-ILD patients could increase the potential for
IGF activity in the lungs, increasing its unbound form.
Conversely to those observations, we identified in our
previous study on IPF patients that IGFBP-1 was in-
creased in untreated patients and reduced under anti-
fibrotic therapy [18].
IGFBP-1 and MMP-9 were selected to be associated
with H3.1 containing cf-nucleosomes because of their
correlation with lung disease [34, 35]. By associating
those 3 biomarkers, we showed a clear improvement in
the potential value of such biomarkers. Our model in
that context allowed to discriminate SSc and SSc-ILD
with a sensitivity of 58% at 80% of specificity. Of interest,
this model is significantly associated with lung volume at
baseline and has a predictive power over the lung dys-
function (assessed by DLCO (% pred) at T2).
SSc-ILD is a major comorbidity in SSc patients driving
the mortality of the disease. In the context of new
proven anti-fibrotic drug therapy (Scensis and Inbuild
trial) [36, 37], specific biomarkers are highly needed to
identify patients at high risk of progressive lung disease
[1]. Therefore, further longitudinal exploratory studies
should be performed in order to evaluate the potential
of such diagnostic and predictive model.
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Additional file 1: Table S1. Correlation between biomarkers and
pulmonary function tests. Correlation of each individual biomarkers: H3.1,
IGFBP-1 and MMP-9 at the baseline level of biomarkers T1 and at T2 (be-
tween 6 and 18 months after T1) and pulmonary functions tests.
Additional file 2: Table S2. Sensitivity at 90% specificity of the
individual biomarkers: Nu.Q™ H3.1, IGFBP-1, MMP-9.
Additional file 3: Supplementary Figure 1. ROC curve for the
discrimination of SSc vs. SSc-ILD. The area under the curve (AUC) reached
0.68 for H3.1 with a diagnostic sensitivity of 32% at 90% specificity.
Additional file 4: Supplementary Figure 2. Interaction plot from the
Two-Way ANOVA expressing the means for the probability of SSc-ILD
provided by the model, by Gender and by Disease severity (p Disease <
0.001 ; p Gender = 0.046 ; p Disease*Gender = 0.027).
Additional file 5: Supplementary Figure 3. Roc Curve for
discrimination of SSc vs SSc-ILD in models containing a combination of
only two biomarkers in comparison with the model combining the three
biomarkers H3.1 containing cf-nucleosome associated, IGFBP-1 and MMP-
9. The model combining the three biomarkers H3.1 containing cf-
nucleosome associated, IGFBP-1 and MMP-9 reached a sensitivity of 42%
at 90% Specificity (AUC 0.77; p Model < 0.001 ; p Nu.Q H3.1 = 0.022 ; p MMP-9
= 0.047 ; p IGFBP-1 = 0.01 ; R
2 = 28%). The model combining the two bio-
markers: cf-nucleosome H3.1 and IGFBP-1 reached an AUC of 0.75 and a
sensitivity at 90% specificity of 48% (p Model < 0.001 ; p Nu.Q H3.1 = 0.010 ;
p IGFBP-1 = 0.013 ; R
2 = 23%). The model combining the two biomarkers
H3.1 and MMP-9 reached an AUC of 0.69 and a sensitivity at 90% specifi-
city of 32% (p Model = 0.005 ; p Nu.Q H3.1 = 0.014 ; p MMP-9 = 0.115 ; R
2 =
14% ). We noted a loss of power with these two models compared to
the model combining the three biomarkers. In addition, in the model
combining H3.1 and MMP-9, the biomarker MMP-9 isn’t significant (p=
0.115) inside the model.
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